Abstract
Epilepsy is among the most common serious neurological disorder and affects at least 50 million people
worldwide. Almost 30% of epileptic patients suffer from various difficulties i.e. pharmacoresistance, which is
associated with social isolation, dependent behavior, unemployment, psychological issues and reduced quality of
life. Considering that the conventional first-generation antiepileptic drugs took more than 70 years to license, the
past 22 years have been truly amazing and there are now more than 20 antiepileptic drugs that can be prescribed
on a long-term basis for the management of epilepsy. Currently available antiepileptic drugs have a limited
efficacy, limited their use and difficulties in patient management. Antiepileptic drugs can provide only
symptomatic relief as these drugs suppress seizures but do not have ability to cure epileptogenesis.
The long term use of antiepileptic drugs can cause adverse effects, withdrawal symptoms, deleterious
interactions with other drugs and economic burden. Furthermore, some of the available antiepileptic drugs may
even potentiate certain type of seizures.. This review will highlight the recent advancement in AEDs, i.e. used in
the treatment and management of epilepsy.
KEYWORDS: antiepileptic, seizure, pharmacoresistance, recent developments.